FloodLAMP Surveillance, Testing, and Screening During the COVID-19 Pandemic Regulatory history and analysis of surveillance, testing, and screening distinctions during the COVID-19 pandemic, focusing on how "surveillance testing" was defined, contested, and regulated across U.S. programs (2020--2023). Covers FDA/CMS/CDC frameworks, key case studies (SCAN, SafeGuard/New Trier, FloodLAMP), wastewater and genomic surveillance, and post-PHE transitions, with appendices mapping FloodLAMP archive documents and primary sources. ai file regulatory surveillance _AI_Covid_Surveillance_Testing_Screening_Report.md regulatory/surveillance/_AI_Covid_Surveillance_Testing_Screening_Report.md 2026_03_01 Created by ChatGPT Pro 5.2 Extended during archive preparation. **NOT HUMAN VERIFIED - MAY CONTAIN ERRORS** Comprehensive report on surveillance, testing, and screening regulatory history during the COVID-19 pandemic, covering U.S. regulatory architecture (FDA/CMS/CDC), key case studies (SCAN, SafeGuard/New Trier, FloodLAMP), operational patterns, and post-PHE transitions. Prompt not included. surveillance, screening, testing, CLIA, FDA, CMS, CDC, regulatory-definitions, SCAN, wastewater, genomic-surveillance md CC BY 4.0 - https://creativecommons.org/licenses/by/4.0/ 4205 8194 gfile-url xfile-github-download-url pdf-gdrive-url pdf-github-url github-markdown-url github-markdown-download-url web-pdf-url web-slides-url youtube-url web-url